The international tumor-specific antigen cancer vaccine sector is currently experiencing a rapid period of expansion, fueled by substantial progress in personalized medicine and a rising awareness of the immune system's function in combating cancers. Forecasts indicate a sustained increase in the next years, driven by clinical studies demonstrating